Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kala Bio Inc (NQ: KALA )

7.000 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.000
Bid (Size) 6.860 (1)
Ask (Size) 7.600 (2)
Prev. Close 7.000
Today's Range 7.000 - 7.000
52wk Range 5.108 - 19.35
Shares Outstanding 2,816,454
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire

Performance

YTD
+0.72%
+0.72%
1 Month
-9.09%
-9.09%
3 Month
-10.83%
-10.83%
6 Month
-12.50%
-12.50%
1 Year
-58.01%
-58.01%

More News

Read More
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From KALA BIO, Inc.
Via GlobeNewswire
Kala Bio: Q3 Earnings Insights
Via Benzinga
Kala Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
Where Kala Pharmaceuticals Stands With Analysts
Via Benzinga
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Participate in Upcoming Investor Conferences in August
From KALA BIO, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Name Change to KALA BIO
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Aeglea Biotherapeutics, Toro Corp, AirSculpt, A Company Moves Up 4,166 Positions & More
Via Benzinga
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More
Via Benzinga
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
5 Short Squeeze Stocks To Watch: Getty Images, Bullfrog AI And A New Leader For The Week
Via Benzinga
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.